CN103007231A - Medicine for treating Bantis syndrome - Google Patents

Medicine for treating Bantis syndrome Download PDF

Info

Publication number
CN103007231A
CN103007231A CN2012105780744A CN201210578074A CN103007231A CN 103007231 A CN103007231 A CN 103007231A CN 2012105780744 A CN2012105780744 A CN 2012105780744A CN 201210578074 A CN201210578074 A CN 201210578074A CN 103007231 A CN103007231 A CN 103007231A
Authority
CN
China
Prior art keywords
parts
medicine
syndrome
bantis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2012105780744A
Other languages
Chinese (zh)
Other versions
CN103007231B (en
Inventor
王西英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qin Qingxiang
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201210578074.4A priority Critical patent/CN103007231B/en
Publication of CN103007231A publication Critical patent/CN103007231A/en
Application granted granted Critical
Publication of CN103007231B publication Critical patent/CN103007231B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a medicine for treating Bantis syndrome to solve the problem of treatment of the Bantis syndrome. The medicine is characterized by being processed by the following traditional Chinese medicines by weight: 6-10 parts of penthorum chinense pursh, 8-15 parts of rust-coloured crotalaria herb with root, 8-15 parts of catclaw buttercup root, 6-10 parts of stringy stonecrop herb, 6-10 parts of pangolin scales, 8-15 parts of adsuki bean, 6-10 parts of common anemarrhena rhizome, 8-15 parts of immature orange fruit and 3-6 parts of dried ginger. Clinical experiments prove that used for treating Bantis syndrome, the medicine has the characteristics of good curative effect and higher safety and deserves clinical application and promotion.

Description

A kind of medicine for the treatment of banti's syndrome
Technical field
The present invention relates to the field of Chinese medicines, be specifically related to treat the medicine of banti's syndrome.
Background technology
Banti's syndrome (Bantis syndrome), it is a kind of agnogenio congested chronic progressive disease, clinical characters is the enlargement of chronic progressive external spleen, carrying out property anemia, leukocyte and thrombocytopenia and digestive tract hemorrhage are main manifestations, late period occurs the signs such as ascites, jaundice, hepatic insufficiency and liver cirrhosis.
Banti's syndrome often causes portal vein by a variety of causes and blocks and cause.The splenic vein belongs to portal system, and normal person 70% splenic vein blood imports portal vein.If portal vein blocks, banti's syndrome can appear in the blood back obstacle of spleen.The spleen of removing enlargement when the reason of hyperemia can bounce back.Late case is owing to fibrous tissue and reticuloendotheliosis, even remove the cause of disease, splenomegaly is also without obviously bouncing back.Think that at present this levies not is an independently disease, but because one group of symptom of chronic Portal Venous Obstruction or the caused portal hypertension of liver cirrhosis, height splenomegaly, anemia and hypersplenism.
Children's causes that the main cause of portal hypertension is portal vein and thrombosis of splenic vein period, and morbidity is slow, and Chang Yin chances on splenomegaly and causes that the head of a family notes.Children's's general state is better, without the hepatopathy sign.Some infants in early days take abdominal discomfort, dyspepsia, weak pale, lay one's hand on and upper left abdominal lump (splenomegaly) as main manifestations.Hemogram checking presents anemia in various degree, leukopenia, and platelet is normal or slight to be reduced, and defective blood clot retraction and capillary fragility test are positive.The bone marrow smear inspection is early stage to be changed without unusual, sometimes is the visible erythroblast of hypertrophy phenomenon and megalokaryocyte and increases and see the cell maturation obstacle.Mid-term, granulocyte and Megakaryocytic maturation can be restricted, and late period, the erythrocyte maturation was affected.
The treatment of banti's syndrome mainly is row splenectomy operation, and liver external form portal hypertension also has the esophageal varicosis person should door-body circulation bypass.But there is following defective in above-mentioned operative treatment: 1. the requirements of operation children's age is more than 6 years old; 2. the case take hepatitis interstitialis chronica as the master is because hepatocyte has grievous injury, and operative treatment there is no benifit.
So the banti's syndrome of children's below 6 years old there is no definite therapeutic scheme, only is supporting treatment, such as high protein, high-carbohydrate meals multivitamin, chalybeate or liver agent are powerful to anemia, give in case of necessity blood transfusion.Therefore, clinically still lack a kind of child of being specifically designed to, and the medicine of the light treatment banti's syndrome of untoward reaction.
Summary of the invention
Technical assignment of the present invention is for above the deficiencies in the prior art, and the medicine of the treatment banti's syndrome that a kind of curative effect is sure, untoward reaction is light is provided.
The technical scheme that the present invention solves its technical problem is: a kind of medicine for the treatment of banti's syndrome, it is characterized in that being processed by plurality of Chinese, its composition of raw materials and weight proportion are: 6 ~ 10 parts of Penthorum chinense, 8 ~ 15 parts of Herba Crotalariae Ferrugineaes, 8 ~ 15 parts of Radix Ranunculi Ternatis, 6 ~ 10 parts of Herba Sedis, 6 ~ 10 parts of Squama Maniss, 8 ~ 15 parts of Semen Phaseolis, 6 ~ 10 parts of the Rhizoma Anemarrhenaes, 8 ~ 15 parts of Fructus Aurantii Immaturuss, 3 ~ 6 parts of Rhizoma Zingiberiss.
Its optimum weight proportioning is: 8 parts of Penthorum chinense, 10 parts of Herba Crotalariae Ferrugineaes, 10 parts of Radix Ranunculi Ternatis, 8 parts of Herba Sedis, 8 parts of Squama Maniss, 10 parts of Semen Phaseolis, 8 parts of the Rhizoma Anemarrhenaes, 10 parts of Fructus Aurantii Immaturuss, 5 parts of Rhizoma Zingiberiss.
Wherein said: Penthorum chinense, for Crassulaceae penthorum plant Penthorum chinense Penthorum chinense Pursh, with all herbal medicine.Nature and flavor are sweet, temperature.But the dehumidifying of merit diuretic, stasis-dispelling and pain-killing.
Herba Crotalariae Ferrugineae is leguminous plant falsely herb or the whole herb with root of blue rotalaria ferruginea Grah..The bitter little acid of nature and flavor; Flat cold.Return liver, lung meridian.But the merit nourishing the kidney and liver, relieving cough and asthma, eliminating damp, detoxifying.
Radix Ranunculi Ternati is the dried root of the little Herba Ranunculi Japonici Ranunculus of ranunculaceae plant ternatus Thunb..Nature and flavor are sweet, hot, temperature.Return liver, lung meridian.But the merit eliminating stagnation, detumescence.
Herba Sedi is the fresh or dry herb of Crassulaceae herbaceous plant Herba Sedi SedumsarmentoswrBge..Sweet, light, the little acid of nature and flavor, cold.Return liver, gallbladder, small intestine meridian.But merit dampness removing jaundice eliminating, heat-clearing and toxic substances removing.
Squama Manis is the scute of Manidae animal Squama Manis Manis pentadactyla Linnaeus.Nature and flavor are salty, are slightly cold.Return liver, stomach warp.The merit stimulating milk secretion of can stimulating the menstrual flow, detumescence and apocenosis, expel wind to dredge collateral.
Semen Phaseoli is the dry mature seed of leguminous plant Semen Phaseoli or Semen Phaseoli.Nature and flavor are sweet, sour, and are flat.GUIXIN, small intestine meridian.But the merit inducing diuresis to remove edema, removing toxic substances and promoting pus discharge.
The Rhizoma Anemarrhenae is the dry rhizome of liliaceous plant Rhizoma Anemarrhenae Anemarrhena asphodeloides Bunge..Nature and flavor are bitter, sweet, and are cold.Return lung, stomach, kidney channel.But the merit clearing away heat-fire promotes the production of body fluid and moisturizes.
Fructus Aurantii Immaturus is the dry young fruit of rutaceae Citrus aurantium Linn. Citrus aurantium L. and variety or Fructus Citri sinensis Citrus sinensis Osbeck.But merit dispelling the stagnated QI intestinal stasis relieving.Nature and flavor are bitter, hot, sour, temperature.Return spleen, stomach warp.But merit dispelling the stagnated QI removing food stagnancy, the loose painful abdominal mass of reducing phlegm.
Rhizoma Zingiberis is the dry rhizome of zingiber Zingiber officinale Rosc..Nature and flavor are hot, hot.Return spleen, stomach, kidney, the heart, lung meridian.But the merit warming spleen and stomach for dispelling cold, recuperating depleted YANG is promoted blood circulation, the dampness expectorant.
Composition principle: banti's syndrome often causes portal vein by a variety of causes and blocks and cause.So many invigorating blood circulation from dispelling the stagnated QI of present treatment started with, but this kind rule for the treatment of clinical efficacy is also bad, and the anxiety of blood is arranged, the blind expansion blood vessel easily causes fragile blood vessel wall and breaks, and inspires hematemesis.And the young sun of the young the moon of children's, the medicine of tiger and wolf is easily hindered its nephroyin and nephroyang, and yin and yang imbalance is not normal, easily causes on the contrary primary disease to develop.
The present invention has following characteristics compared with the prior art:
1, prescription is unique: avoid using the medicine of the moving blood of circulation of qi promoting, and select the medicine in Tonghua, from dampness removing stimulate the menstrual flow into, and cooperate the heat clearing away medicine; Select the supplementary inhibitory medicine thing, so that prescription is steady;
2, inventor's clinical experience gained for many years uses Penthorum chinense, Herba Crotalariae Ferrugineae, Radix Ranunculi Ternati, and three herbal medicines cooperate, the be impairment of the kidney anxiety of the moon of the effectively symptom of rapid recovery children's banti's syndrome, and nothing; Wherein Herba Crotalariae Ferrugineae also has reinforcement and elimination in combination, and the Radix Ranunculi Ternati eliminating stagnation can delay further splenomegaly;
3, the use of supplementary drug thing, consider from kidney and taste many-side: select the Herba Sedi eliminating damp-heat, inventor's clinical research shows, adds rapidly relieve portal hypertension of this medicine, especially is fit to the unconspicuous case of clinical symptoms; Choose Squama Manis collateral dredging, the thick gas of Semen Phaseoli diuretic; The Rhizoma Anemarrhenae is given birth to clearly the moon and is gone asthenic fire; Fructus Aurantii Immaturus is used for the loose painful abdominal mass of the spleen-stomach disease dispelling the stagnated QI originally, but inventor's clinical experience show, in we, add Fructus Aurantii Immaturus, can reach the effect of regulating local mechanism of qi, and cooperate with the Rhizoma Anemarrhenae, Fructus Aurantii Immaturus also has the effect of tying-in, makes Rhizoma Anemarrhenae effect can be extended down to middle Jiao;
4, medicine is to being combined with characteristic: Fructus Aurantii Immaturus draws the Rhizoma Anemarrhenae to middle Jiao; Fructus Aurantii Immaturus cooperates Squama Manis to relieve local mechanism of qi but does not consume gas; Herba Sedi cooperates with Herba Crotalariae Ferrugineae, and then Herba Sedi can also be as liver and gall through guiding drug;
5, using corrigent medicine: choose the Rhizoma Zingiberis warming YANG and promoting blood circulation, make the gas that silk silk warming YANG is arranged in the cold medicine;
6, medicine material consumption of the present invention is groped to sum up to draw through the inventor in a large number, and each raw material consumption is for all to have preferably curative effect in the following weight parts scope.
The specific embodiment
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, the crude drug weight proportion: Penthorum chinense 6g, Herba Crotalariae Ferrugineae 8g, Radix Ranunculi Ternati 8g, Herba Sedi 6g, Squama Manis 6g, Semen Phaseoli 8g, Rhizoma Anemarrhenae 6g, Fructus Aurantii Immaturus 8g, Rhizoma Zingiberis 3g.
Embodiment 2, the crude drug weight proportion: Penthorum chinense 10g, Herba Crotalariae Ferrugineae 15g, Radix Ranunculi Ternati 15g, Herba Sedi 10g, Squama Manis 10g, Semen Phaseoli 15g, Rhizoma Anemarrhenae 10g, Fructus Aurantii Immaturus 15g, Rhizoma Zingiberis 6g.
Embodiment 3, the crude drug weight proportion: Penthorum chinense 8g, Herba Crotalariae Ferrugineae 10g, Radix Ranunculi Ternati 10g, Herba Sedi 8g, Squama Manis 8g, Semen Phaseoli 10g, Rhizoma Anemarrhenae 8g, Fructus Aurantii Immaturus 10g, Rhizoma Zingiberis 5g.
During use, Chinese medicine Penthorum chinense of the present invention, Herba Crotalariae Ferrugineae, Radix Ranunculi Ternati, Herba Sedi, Squama Manis, Semen Phaseoli, the Rhizoma Anemarrhenae, Rhizoma Zingiberis and Fructus Aurantii Immaturus are decocted with water twice, merging filtrate, a minute morning and evening takes.Above-mentioned drug dose is the odd-numbered day amount, and the child gets full dose more than 10 years old, gets half amount, chooses 1/4 and measure in 1 ~ 5 years old in 5 ~ 10 years old.
Effective combination of said medicine is coordinated mutually, can effectively reach the purpose for the treatment of banti's syndrome, and side effect is less.The above results is the clinical data sufficient proof, and interrelated data is as follows, and wherein drugs uses and is the crude drug weight proportion among the embodiment 3.
1 object and method.
1.1 object: choose banti's syndrome 48 examples of in January, 2009 ~ 2012 year JIUYUE age between 2 ~ 6 years old, infant all meets the banti's syndrome diagnostic criteria, and the equal nutriture of each case is good, side by side except the blood vessel congenital malformation.Male 20 examples wherein, women 28 examples, 2 ~ 4 years old 22 example, 4 ~ 6 years old 26 example.Be divided into matched group 24 examples, experimental group 24 examples, two groups of sexes, age ratio, difference does not have statistical significance (P〉0.05).
1.2 method.
1.2.1 research method: matched group is taked supporting treatment, gives high protein, high-carbohydrate meals multivitamin, the anemia infant is added use chalybeate, gives in case of necessity blood transfusion; Experimental group adds with the embodiment of the invention 3 gained treatments by Chinese herbs in the treatment of control group scheme, gets half amount, chooses 1/4 and measure in 2 ~ 4 years old in 4 ~ 6 years old.
1.2.2 evaluation index: 7d, 14d, 28d promoting the circulation of blood routine examination and Abdominal B type ultrasonography inspection after the treatment.
1.2.3 safety evaluatio: all carry out hepatic and renal function before and after the medication and detect.
1.2.4 statistical analysis: carry out statistical analysis with SPSS 13.0, P<0.05 expression has significant.
2 results.
2.1 effective percentage is relatively between two groups: after treating rear 28 days, the matched group effective percentage is 62.50%(15/24), the treatment group effective percentage is 91.67%(22/24), the two compares, and treatment group obviously is better than matched group (P<0.05).
2.2 untoward reaction: two groups of infants have no any Reporting of harms.
3. conclusion.
The prompting of this result of study, the present invention treats children's's banti's syndrome and has good effect and the higher characteristics of safety, and clinic is used, is promoted.

Claims (2)

1. medicine for the treatment of banti's syndrome, it is characterized in that being processed by plurality of Chinese, its composition of raw materials and weight proportion are: 6 ~ 10 parts of Penthorum chinense, 8 ~ 15 parts of Herba Crotalariae Ferrugineaes, 8 ~ 15 parts of Radix Ranunculi Ternatis, 6 ~ 10 parts of Herba Sedis, 6 ~ 10 parts of Squama Maniss, 8 ~ 15 parts of Semen Phaseolis, 6 ~ 10 parts of the Rhizoma Anemarrhenaes, 8 ~ 15 parts of Fructus Aurantii Immaturuss, 3 ~ 6 parts of Rhizoma Zingiberiss.
2. a kind of medicine for the treatment of banti's syndrome according to claim 1 is characterized in that its weight proportion is: 8 parts of Penthorum chinense, 10 parts of Herba Crotalariae Ferrugineaes, 10 parts of Radix Ranunculi Ternatis, 8 parts of Herba Sedis, 8 parts of Squama Maniss, 10 parts of Semen Phaseolis, 8 parts of the Rhizoma Anemarrhenaes, 10 parts of Fructus Aurantii Immaturuss, 5 parts of Rhizoma Zingiberiss.
CN201210578074.4A 2012-12-27 2012-12-27 Medicine for treating Bantis syndrome Expired - Fee Related CN103007231B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210578074.4A CN103007231B (en) 2012-12-27 2012-12-27 Medicine for treating Bantis syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201210578074.4A CN103007231B (en) 2012-12-27 2012-12-27 Medicine for treating Bantis syndrome

Publications (2)

Publication Number Publication Date
CN103007231A true CN103007231A (en) 2013-04-03
CN103007231B CN103007231B (en) 2014-08-20

Family

ID=47956695

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201210578074.4A Expired - Fee Related CN103007231B (en) 2012-12-27 2012-12-27 Medicine for treating Bantis syndrome

Country Status (1)

Country Link
CN (1) CN103007231B (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102988951A (en) * 2012-12-27 2013-03-27 武英 Medicine for treating children with congestive splenomegaly
CN103007228A (en) * 2012-12-27 2013-04-03 李莉 Medicine for treating infantile nephrotic syndrome
CN104436126A (en) * 2014-11-25 2015-03-25 四川金堂海纳生物医药技术研究所 Orally taken drug for treating Bantis syndrome and preparation method thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102247547A (en) * 2010-12-16 2011-11-23 姜绪东 Prescription for treating hepatitis
CN102988951A (en) * 2012-12-27 2013-03-27 武英 Medicine for treating children with congestive splenomegaly
CN103007228A (en) * 2012-12-27 2013-04-03 李莉 Medicine for treating infantile nephrotic syndrome

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102247547A (en) * 2010-12-16 2011-11-23 姜绪东 Prescription for treating hepatitis
CN102988951A (en) * 2012-12-27 2013-03-27 武英 Medicine for treating children with congestive splenomegaly
CN103007228A (en) * 2012-12-27 2013-04-03 李莉 Medicine for treating infantile nephrotic syndrome

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
《中医杂志》 20031031 侯林毅 陈昭定治疗小儿班替综合征经验 , 第10期 *
《中国中医急症》 20110331 侯林毅等 陈昭定教授运用活血化瘀法治疗小儿疾病的经验 第20卷, 第03期 *
侯林毅: "陈昭定治疗小儿班替综合征经验", 《中医杂志》 *
侯林毅等: "陈昭定教授运用活血化瘀法治疗小儿疾病的经验", 《中国中医急症》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102988951A (en) * 2012-12-27 2013-03-27 武英 Medicine for treating children with congestive splenomegaly
CN103007228A (en) * 2012-12-27 2013-04-03 李莉 Medicine for treating infantile nephrotic syndrome
CN102988951B (en) * 2012-12-27 2014-05-21 武英 Medicine for treating children with congestive splenomegaly
CN103007228B (en) * 2012-12-27 2015-03-18 迟彩霞 Medicine for treating infantile nephrotic syndrome
CN104436126A (en) * 2014-11-25 2015-03-25 四川金堂海纳生物医药技术研究所 Orally taken drug for treating Bantis syndrome and preparation method thereof

Also Published As

Publication number Publication date
CN103007231B (en) 2014-08-20

Similar Documents

Publication Publication Date Title
CN101433654B (en) Chinese medicine preparation for treating women's chronic pelvic inflammatory disease and preparation method thereof
CN103169923B (en) Traditional Chinese medicine composition for treating myocarditis and preparation method of traditional Chinese medicine composition
CN103007228B (en) Medicine for treating infantile nephrotic syndrome
CN103007231B (en) Medicine for treating Bantis syndrome
CN103007230B (en) Medicine for treating interstitial cystitis
CN102309740B (en) Traditional Chinese medicine for treating chronic enteritis
CN103520669B (en) The Chinese medicine for the treatment of phlegm-damp accumulation symptom pattern of syndrome obstruction of qi in the chest and cardialgia
CN102988951B (en) Medicine for treating children with congestive splenomegaly
CN104399039A (en) Medicament for treating ulcerative colitis and preparation method thereof
CN102988953B (en) Medicine for treating prenatal urinary tract infection
CN101077412A (en) Method for treating chronic colitis
CN103520652B (en) Traditional Chinese medicine composition for treating liver cancer
CN101745043A (en) Traditional Chinese medicine composite used for curing pregnant jaundice of newborn infant
CN102293887B (en) Dissipating and discharging capsules for treating biliary, gastric and intestinal diseases
CN105362682A (en) External-use medicine for treating hypomenorrhea
CN104587281A (en) Spleen invigoration and diuresis promoting traditional Chinese medicine composition for treating cirrhosis and preparation
CN103948856A (en) Traditional Chinese medicament for treating artories and veims stasis syndrome chest stuffiness and pains
CN100408082C (en) Chinese medicine for treating liver
CN102698240B (en) Chinese medicinal granule for treating chronic nonspecific ulcerative colitis
CN103007232A (en) Medicine for treating infantile urinary tract infection
CN104888017A (en) Medicine for treating hepatitis B
CN104771705A (en) Traditional Chinese medicine preparation for treating chronic nephritis
CN105031600A (en) Suppository treating acute infantile diarrhea and preparation method thereof
CN104940819A (en) Traditional Chinese medicine composition for treating fetal jaundice and preparing method of traditional Chinese medicine composition
CN105125733A (en) Traditional Chinese medicine for treating pollinosis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: QIN QINGXIANG

Free format text: FORMER OWNER: WANG XIYING

Effective date: 20140716

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Qin Qingxiang

Inventor after: Ma Zhigang

Inventor before: Wang Xiying

COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 276826 RIZHAO, SHANDONG PROVINCE TO: 261500 WEIFANG, SHANDONG PROVINCE

Free format text: CORRECT: INVENTOR; FROM: WANG XIYING TO: QIN QINGXIANG MA ZHIGANG

TA01 Transfer of patent application right

Effective date of registration: 20140716

Address after: 261500 obstetrics and Gynecology, Gaomi City Hospital of traditional Chinese medicine, 588 Fenghuang street, Weifang, Shandong, Shandong, Gaomi City

Applicant after: Qin Qingxiang

Address before: 276826 port hospital, No. 58, the Yellow Sea, Shandong, Rizhao City

Applicant before: Wang Xiying

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140820

Termination date: 20141227

EXPY Termination of patent right or utility model